Risk factors for mortality in COVID-19 patients in sub-Saharan Africa: A systematic review and meta-analysis

Factors associated with mortality among patients aged 12 years and above requiring hospitalization for severe respiratory illness (SRI): Findings from the COVID-19 vaccine effectiveness evaluation in Kenya and Mali, 2022-2023

BACKGROUND

Mortality attributed to respiratory illnesses is well characterized in children <5 years. However, there is paucity of data among older populations. Here, we leveraged data from the COVID-19 Vaccine Effectiveness Evaluation to establish the factors associated with mortality among patients with severe respiratory illness (SRI) in Kenya and Mali.

METHODS

We enrolled patients (≥ 12 years) requiring hospitalization for SRI, defined as acute onset (≤ 14 days) of at least two of the following: cough, fever (reported/measured temperature of ≥38 °C), chills, rigors, myalgia, headache, sore throat, fatigue, congestion or runny nose, loss of taste or smell, or pneumonia diagnosis, from referral hospitals in Kenya and Mali. We collected demographic, clinical characteristics of the patients, and nasopharyngeal and oropharyngeal specimens for SARS-CoV-2 testing using RT-PCR. A mixed-effects logistic regression model was fitted to identify factors associated with 30-day mortality among patients with SRI.

RESULTS

Between July 2022 and October 2023 9947 SRI patients were enrolled, of whom 9743 were included in this analysis and 1620 (16.6 %) died (Kenya: 1533/7822 [20.0 %]; Mali: 87/1921 [4.5 %]). Compared to patients aged 12-24 years, those aged >64 years were more likely to die (adjusted Odds Ratio [aOR] = 2.36; 95 % Confidence Interval [95 % CI] 1.72-3.24). Patients who were in coma (aOR = 3.45; 95 %CI 2.27-5.24) or Intensive Care Unit (aOR = 2.98; 95 %CI 2.06-4.31), or had HIV infection (aOR = 2.47; 95 %CI 2.11-2.90), liver disease (aOR = 2.42; 95 %CI 1.57-3.74), cancer (aOR = 2.09; 95 %CI 1.46-2.99) or SARS-CoV-2 infected (aOR = 1.24; 95 %CI 1.02-1.52) were at increased risk of death. Additionally, diarrhea, malaise/fatigue, difficulty in breathing, confusion, mechanical ventilation, vasopressor support, malnutrition and admission to High Dependency Unit had significant associations.

CONCLUSION

Mortality was heightened among SRI patients who were older, required critical care, had chronic conditions and infected with SARS-CoV-2 suggesting need for early identification of these conditions to improve possible treatment outcomes.

Association between excess mortality due to COVID-19, full vaccination coverage, smoking, hypertension, and gross domestic product per capita/purchasing power parity across 10 Southeast Asian Countries

Objectives

Mass vaccination and cardiometabolic disorders have been reported to influence COVID-19 prognosis and mortality burden. We applied a generalized linear mixed model (GLMM) to explore the associations between COVID-19 mortality, full vaccination coverage, and cardiometabolic health indicators in Southeast Asia (SEAR).

Methods

A region-wide ecological analysis of aggregate COVID-19 data from 10 SEAR countries (January 2020 to December 2022) was performed. The databases used were from the John Hopkins University Coronavirus Resource Center and the WHO Health Organization. Excess deaths associated with COVID-19 per 100,000 and case fatality rate were the outcome variables. A GLMM was performed to determine the predictors of COVID-19 mortality, and adjustments were made for sociodemographic variables. The statistical significance level was set at P <0.01 (double-sided).

Results

The adjusted GLMM analysis showed that the number of excess deaths due to COVID-19 per 100,000 was strongly and positively associated with age-standardized smoking (coefficient of determination [coeff.] = 9.18 [standard error (SE): 2.15]; P <0.001) and hypertension prevalence (coeff. = 25.98 [SE: 9.15]; P <0.01), whereas it was strongly and negatively associated with the full vaccination coverage rate (coeff. = -5.23 [SE: 1.54]; P <0.01) and gross domestic product per capita/purchasing power parity (coeff. = -102.01 [SE: 18.31]; P <0.001). The COVID-19 case fatality rate was positively associated with the age-standardized prevalence of hypertension (coeff. = 0.30 [SE: 0.16]; P <0.01) and negatively correlated with the full vaccination coverage rate (coeff. = -0.05 [SE: 0.01]; P <0.01) and gross domestic product per capita/purchasing power parity (coeff. = -1.09 (SE: 0.34); p<0.001). The associations observed in the multivariate analysis remained in the stratified analysis by quartile.

Conclusions

The study findings suggest that implementing effective public health interventions that would have increased vaccine uptake and improve cardiometabolic health on one hand and initiatives that enhance country-level economy on the other hand would have reduced COVID-19 mortality in the SEAR.

Real-world COVID-19 vaccine effectiveness in Zimbabwe: A test-negative case-control study

Background

COVID-19 vaccination is critical in sub-Saharan Africa to reduce the disease burden. This study assessed real-world vaccine effectiveness (VE) in Zimbabwe.

Aim

To determine COVID-19 VE and factors associated with disease severity and mortality in Zimbabwe.

Setting

The study setting comprised a test-negative case-control study across health facilities in Harare and Bulawayo (May 2023 - August 2023).

Methods

Adults (≥ 18 years) were recruited from COVID-19 registers (1:1 case-control; matched by sex, age and clinic visit date). Telephone interviews assessed vaccination status, disease severity (cases) and comorbidities. Conditional logistic regression estimated VE (1 - odds ratio*100), with stratification by age and comorbidities. Ordinal and simple logistic regression analysed factors associated with disease severity and vaccination-variant relationships.

Results

Overall vaccination coverage was 38% (fully vaccinated including boosters), with 62% unvaccinated. The median age was 38 years (interquartile range [IQR]: 30-50) with more females (n = 352). Overall VE against any COVID-19 infection was 32.2% (95% CI: 8.9, 49.5). Older age (45+ years) and chronic conditions were associated with increased hospitalisation risk. Among cases, hospitalisation rate was 34.8% (n = 174/500) and COVID-19-related mortality rate was 11.6% (n = 58/500).

Conclusion

This study found a moderate VE of COVID-19 vaccines in Zimbabwe, potentially influenced by age, comorbidities and variants. We highlight the need for targeted vaccination strategies and public health measures informed by these findings.

Contribution

This research informs public health strategies to optimise vaccination efforts and improve health outcomes across Africa, aligning with the journal's focus on public health issues.

COVID-19 vaccine uptake, barriers and associated factors among healthcare workers in Malawi

Background

The COVID-19 pandemic led to an urgent need for a global vaccine. Despite being a priority group, the vaccine uptake among healthcare workers (HCWs) remains low.

Aim

This article assessed the COVID-19 vaccine uptake and its associated barriers in Malawi.

Setting

A cross-sectional study was conducted among HCWs in Malawi's Blantyre, Lilongwe and Mzuzu districts from 11 April 2023 to 14 April 2023.

Methods

Proportionally distributed among various cadres, 200 participants were randomly selected. A structured questionnaire was administered, assessing HCWs' uptake, willingness, attitudes and barriers to COVID-19 vaccines. Data were managed in REDCap and analysed using STATA version 14. Frequencies and percentages were computed. Variables with p-value ≤ 0.25 were included in the multivariable modified passion model.

Results

A total of 175 (88%) participants received a single-dose vaccine, while only 11.5% received a booster. Vaccine uptake was associated with age groups 25-34 years (aPR = 2.35, 95% CI: 1.21, 4.60) and 35-44 years (aPR = 2.30, 95% CI: 1.18, 4.50), being a nurse/midwife (aPR = 0.86, CI: 0.74, 0.99) and laboratory personnel (aPR = 0.86, 95% CI: 0.74, 0.99). Unvaccinated HCWs were concerned about vaccine side effects and lacked trust in the development process.

Conclusion

Issues of vaccine safety, side effects and lack of trust in the vaccine should be addressed. Promoting awareness of vaccine development and benefits, targeting all age groups and cadres, is required among HCWs.

Contribution

The findings can be utilised to develop specific interventions on age and cadre to promote vaccine acceptance among HCWs, in countries with similar contextual settings to Malawi.

Social health gradient and risk factors among patients hospitalized for COVID-19 and pre-pandemic respiratory infections. A linked national individual case-control study in Belgium

Introduction

The literature establishes a clear social gradient in health for transmissible respiratory diseases. However, this gradient's extent remains largely unexplored in the context of COVID-19, and it is uncertain whether the pandemic has exacerbated this gradient. The study aims to compare the socio-economic profiles and comorbidities during the COVID-19 pandemic with a control population affected by viral pneumonia/respiratory disease in 2019.

Methods

This case-control study analyzed linked data from all patients hospitalized for COVID-19 in 2020 (n = 22,087) and for respiratory diseases in 2019 (n = 7,586). Socio-economic data from the social security database were linked to clinical data from the hospital registry. We analyzed the socio-demographic and clinical factors associated with COVID-19 hospitalization (control group, wave 1, and wave 2) using multinomial regressions and logistic regression models and the length of stay during hospitalization using binomial negative regressions.

Results

A social health gradient was observed in both the COVID-19 and control groups, with a significant increase across waves for COVID-19 (p-trend < 0.0001). Men, people over the age of 45, those with comorbidities, high population density, lower income, lower socio-economic status, and people living in Brussels capital were at higher risk of COVID-19 hospitalization and longer length of stay compared to the control group. Except for sub-Saharan Africans, all patients of foreign nationality had a significantly increased risk of hospitalization (p < 0.001), but a shorter length of stay compared to Belgians.

Conclusion

The socio-health gradient for COVID-19 followed the same pattern as that observed in pre-pandemic respiratory diseases, intensifying in the second wave and among the most deprived groups. This study emphasizes the importance of collecting social data alongside clinical data for a better understanding of social health inequalities and for tailoring health prevention policies.

Clinical effectiveness of nirmatrelvir plus ritonavir for patients with COVID-19 and preexisting psychiatric disorders

OBJECTIVES

This study assessed the clinical effectiveness of the combination of nirmatrelvir and ritonavir (NMV-r) in treating nonhospitalized patients with COVID-19 who have preexisting psychiatric disorders.

METHODS

Patients diagnosed with COVID-19 and psychiatric disorders between 1 March 2020, and 1 December 2022, were included using the TriNetX network. The primary outcome was the composite outcome of all-cause emergency department (ED) visits, hospitalization, or death within 30 days.

RESULTS

Propensity score matching yielded two cohorts of 20,633 patients each. The composite outcome of all-cause ED visits, hospitalization, or death within 30 days was 3.57% (737 patients) in the NMV-r cohort and 5.69% (1176) in the control cohort, resulting in a reduced risk in the NMV-r cohort (HR: 0.657; 95% confidence interval (CI): 0.599-0.720). The NMV-r cohort exhibited a lower risk of all-cause hospitalization (HR: 0.385; 95% CI: 0.328-0.451) and all-cause death (HR: 0.110; 95% CI: 0.053-0.228) compared with the control group.

CONCLUSION

NMV-r could mitigate the risk of adverse outcomes in nonhospitalized patients with COVID-19 and preexisting psychiatric disorders. However, only a limited number of patients in this population received adequate treatment, thus emphasizing the importance of promoting its appropriate use.

Survival of hospitalised COVID-19 patients in Hawassa, Ethiopia: a cohort study

The COVID-19 pandemic, caused by SARS-CoV-2, led to 622,119,701 reported cases and 6,546,118 deaths. Most studies on COVID-19 patients in hospitals are from high-income countries, lacking data for developing countries such as Ethiopia.This study assesses clinical features, demographics, and risk factors for in-hospital mortality in Hawassa, Ethiopia. The research cohort comprises 804 cases exhibiting clinical diagnoses and/or radiological findings and indicative of symptoms consistent with COVID-19 at Hawassa University Comprehensive Specialized Hospital from September 24, 2020, to November 26, 2021. In-hospital mortality rate was predicted using Cox regression. The median age was 45 years, with males making up 64.1% of the population. 173 (21.5%) fatalities occurred, with 125 (72.3%) among males. Male patients had higher mortality rates than females. Severe and critical cases were 24% and 21%. 49.1% had at least one comorbidity, with 12.6% having multiple. Common comorbidities were diabetes (15.9%) and hypertension (15.2%). The Cox regression in Ethiopian COVID-19 patients found that factors like gender, advanced age group, disease severity, symptoms upon admission, shortness of breath, sore throat, body weakness, hypertension, diabetes, multiple comorbidities, and prior health facility visits increased the risk of COVID-19 death, similar to high-income nations. However, in Ethiopia, COVID-19 patients were young and economically active. Patients with at least one symptom had reduced death risk. As a conclusion, COVID-19 in Ethiopia mainly affected the younger demographic, particularly economically active individuals. Early detection can reduce the risk of mortality. Prompt medical attention is essential, especially for individuals with comorbidities. Further research needed on diabetes and hypertension management to reduce mortality risk. Risk factors identified at admission play a crucial role in guiding clinical decisions for intensive monitoring and treatment. Broader risk indicators help prioritize patients for allocation of hospital resources, especially in regions with limited medical facilities. Government's focus on timely testing and strict adherence to regulations crucial for reducing economic impact.

Clinical profiles and mortality predictors of hospitalized patients with COVID-19 in Ethiopia

BACKGROUND

Studying the characteristics of hospitalized Coronavirus Disease 2019 (COVID-19) patients is vital for understanding the disease and preparing for future outbreaks. The aim of this study was to analyze and describe the clinical profiles and factors associated with mortality among COVID-19 patients admitted to Jimma Medical Center COVID-19 Treatment Center (JMC CTC) in Ethiopia.

METHODS

All confirmed COVID-19 patients admitted to JMC CTC between 17 April 2020 and 05 March 2022 were included in this study. Socio-demographic data, clinical information, and outcome variables were collected retrospectively from medical records and COVID-19 database at the hospital. Bivariable and multivariable analyses were performed to determine factors associated with COVID-19 severity and mortality. A P-value < 0.05 was considered statistically significant.

RESULTS

A total of 542 confirmed COVID-19 patients were admitted to JMC CTC, of which 322 (59.4%) were male. Their median age was 48 years (IQR 32-64). About 51% (n = 277) of them had severe COVID-19 upon admission. Patients with hypertension [AOR: 2.8 (95% CI: 1.02-7.7, p = 0.046)], diabetes [AOR: 8.8 (95% CI: 1.2-17.3, p = 0.039)], and underlying respiratory diseases [AOR: 18.8 (95% CI: 2.06-71.51, p = 0.009)] were more likely to present with severe COVID-19 cases. Overall, 129 (23.8%) died in the hospital. Death rate was higher among patients admitted with severe disease [AHR = 5.5 (3.07-9.9) p < 0.001)] and those with comorbidities such as hypertension [AHR = 3.5 (2.28-5.41), p < 0.001], underlying respiratory disease [AHR = 3.4 (1.97-5.94), p < 0.001], cardiovascular disease (CVDs) [AHR = 2.8 (1.73-4.55), p < 0.001], and kidney diseases [AHR = 3.7 (2.3-5.96), p < 0.001].

CONCLUSION

About half of COVID-19 cases admitted to the hospital had severe disease upon admission. Comorbidities such as hypertension, diabetes, and respiratory diseases were linked to severe illness. COVID-19 admissions were associated with high inpatient mortality, particularly among those with severe disease and comorbidities.

Aberrant innate immune profile associated with COVID-19 mortality in Pretoria, South Africa

The African continent reported the least number of COVID-19 cases and deaths of all the continents, although the exact reasons for this are still unclear. In addition, little is known about the immunological profiles associated with COVID-19 mortality in Africa. The present study compared clinical and immunological parameters, as well as treatment outcomes in patients admitted with COVID-19 in Pretoria, South Africa, to determine if these parameters correlated with mortality in this population. The in-hospital mortality rate for the cohort was 15.79%. The mortality rate in people living with HIV (PLWH) was 10.81% and 17.16% in people without HIV (p = 0.395). No differences in age (p = 0.099), gender (p = 0.127) or comorbidities were found between deceased patients and those who survived. All four of the PLWH who died had a CD4+ T-cell count <200 cells/mm3, a significantly higher HIV viral load than those who survived (p = 0.009), and none were receiving antiretroviral therapy. Seven of 174 (4%) patients had evidence of auto-antibodies neutralizing Type 1 interferons (IFNs). Two of the them died, and their presence was significantly associated with mortality (p = 0.042). In the adjusted model, the only clinical parameters associated with mortality were: higher fraction of inspired oxygen (FiO2) (OR: 3.308, p = 0.011) indicating a greater need for oxygen, high creatinine (OR: 4.424, p = 0.001) and lower platelet counts (OR: 0.203, p = 0.009), possibly secondary to immunothrombosis. Overall, expression of the co-receptor CD86 (p = 0.021) on monocytes and percentages of CD8+ effector memory 2 T-cells (OR: 0.45, p = 0.027) was lower in deceased patients. Decreased CD86 expression impairs the development and survival of effector memory T-cells. Deceased patients had higher concentrations of RANTES (p = 0.003), eotaxin (p = 0.003) and interleukin (IL)-8 (p < 0.001), all involved in the activation and recruitment of innate immune cells. They also had lower concentrations of transforming growth factor (TGF)-β1 (p = 0.40), indicating an impaired anti-inflammatory response. The immunological profile associated with COVID-19 mortality in South Africa points to the role of aberrate innate immune responses.

COVID-19 mortality rate and its determinants in Ethiopia: a systematic review and meta-analysis

Background

The COVID-19 mortality rate continues to be high in low-income countries like Ethiopia as the new variant's transmission expands and the countries' limited capacity to combat the disease causes severe outcomes, including deaths. The aim of this study is to determine the magnitude of the COVID-19 mortality rate and its determinants in Ethiopia.

Methods

The main electronic databases searched were PubMed, CINAHL, Google Scholar, and African journals online. The included studies' qualities were assessed independently using the Newcastle-Ottawa scale. The data was extracted in Microsoft Excel spreadsheet format. The pooled effect size and odds ratios with 95% confidence intervals across studies were determined using the random-effects model. I2 is used to estimate the percentage of overall variation across studies due to heterogeneity. Egger's test and funnel plot were used to find the published bias. A subgroup analysis was conducted. The effect of a single study on the overall estimation was determined by sensitivity analysis.

Results

A total of 21 studies with 42,307 study participants were included in the final analysis. The pooled prevalence of COVID-19 mortality was 14.44% (95% CI: 10.35-19.08%), with high significant heterogeneity (I2 = 98.92%, p < 0.001). The risk of mortality from COVID-19 disease was higher for patients with comorbidity (AHR = 1.84, 95% CI: 1.13-2.54) and cardiovascular disease (AHR = 2, 95% CI: 1.09-2.99) than their counterparts without these conditions.

Conclusion

A significant number of COVID-19 patients died in Ethiopia. COVID-19 patients with comorbidities, particularly those with cardiovascular disease, should receive special attention to reduce COVID-19 mortality.

Systematic review registration

https://www.crd.york.ac.uk/PROSPERO/, registration identifier (ID) CRD42020165740.

Association between nirmatrelvir plus ritonavir and the outcomes of non-hospitalized obese patients with COVID-19

OBJECTIVE

To investigate the association between nirmatrelvir plus ritonavir (NMV-r) and the outcomes of non-hospitalized obese patients with coronavirus disease 2019 (COVID-19).

METHODS

This retrospective cohort study used the TriNetX research network to identify non-hospitalized obese adult patients with COVID-19 between 1 January 2022 and 30 June 2023. Propensity score matching was used to match patients receiving NMV-r (NMV-r group) with those not receiving NMV-r (control group). The primary outcome was the compositive outcome of all-cause emergency department (ED) visits, hospitalization or death during the 30-day follow-up period.

RESULTS

Using propensity score matching methods, two cohorts of 30,969 patients each with balanced baseline characteristics were identified. During the follow-up period, the NMV-r group had a lower risk of all-cause ED visits, hospitalization or death [4.80% (n=1489) vs 5.50% (n=1705); hazard ratio (HR) 0.900, 95% confidence interval (CI) 0.839-0.965]. Compared with the control group, the NMV-r group had a lower risk of all-cause ED visits (HR 0.812, 95% CI 0.740-0.891) and all-cause mortality (HR 0.089, 95% CI 0.027-0.288). The lower risk in the NMV-r group compared with the control group was observed consistently in most subgroup analyses according to body mass index (30.0-34.9 kg/m2: HR 0.68, 95% CI 0.55-0.82; 35.0-39.9 kg/m2: HR 0.67, 95% CI 0.52-0.87), age (4-64 years: HR 0.83, 95% CI 0.75-0.92; ≥65 years: HR 0.88, 95% CI 0.79-0.98), sex (men: HR 0.69, 95% CI 0.60-0.79; women: HR 0.69, 95% CI 0.63-0.76) and vaccination status (unvaccinated: HR 0.75, 95% CI 0.70-0.81).

CONCLUSION

NMV-r is associated with reduced risk of all-cause ED visits, hospitalization and death for non-hospitalized obese patients with COVID-19. Accordingly, these findings support the use of NMV-r in obese patients.

A complex intervention on vaccination uptake among older adults (≥ 60 years) in Germany - a study protocol with a mixed methods design

BACKGROUND

The current uptake of many vaccinations recommended for persons aged 60 and older is unsatisfactory in Germany. Lack of confidence in the safety and efficacy of vaccinations, lack of knowledge and insecurities about possible side effects, and numerous pragmatic barriers are just some of the reasons to be mentioned. General practitioners (GPs) play a central role in the vaccination process. Therefore, effective interventions in this context are needed to address the various barriers and improve the vaccination uptake rates.

METHODS

A complex intervention will be implemented and evaluated in 1057 GPs' practices in two German federal states. The components include trainings for GPs and medical assistants on communication psychology, medical aspects, and organisational vaccination processes. The primary outcome influenza vaccination rate and the secondary outcomes vaccination uptake rate of other vaccinations as well as vaccine literacy of patients will be examined. The intervention will be evaluated in a mixed methods study with a controlled design. Survey data will be analysed descriptively and by using mean comparisons as well as multivariable multilevel analyses. The qualitative data will be analysed with qualitative content analysis. The secondary data will be analysed by using descriptive statistics, a pre-post comparison by performing mean comparisons, cluster analysis, and subgroup analyses.

DISCUSSION

In this study, a complex intervention to improve vaccination rates in GP practices for the vaccinations recommended for people aged 60 years and older will be implemented and evaluated. Additionally, improvements in patients' vaccine-related health literacy and knowledge, and patients' intention to get vaccinated are expected. The mixed methods design can deliver results that can be used to improve preventive health care for elderly people and to gain more knowledge on vaccination uptake and the intervention's effectiveness.

TRIAL REGISTRATION

Trial registration number: DRKS00027252 (retrospectively registered).

COVID-19 in-hospital mortality during the first two pandemic waves, at Helen Joseph Hospital, South Africa

Introduction

there has been significant global variation in Coronavirus Disease (COVID-19) mortality at different time points in the pandemic. Contributing factors include population demographics, comorbidities, health system capacity, prior infection with COVID-19, vaccinations, and viral variants. The study aims to describe COVID-19-related mortality of inpatients at Helen Joseph Hospital (HJH), over 12 months, during the first two waves of the COVID-19 pandemic in South Africa. The primary objectives were to describe the socio-demographic details, clinical characteristics, and hospital outcomes during the first and second waves of COVID-19. This included an assessment of the in-hospital case fatality ratio (CFR) of patients admitted with COVID-19. The secondary objectives were to compare the socio-demographic details, clinical characteristics, and outcomes between the two waves, and to determine risk factors associated with COVID-19-related mortality.

Methods

this is a retrospective cohort study of all inpatient laboratory-confirmed COVID-19 cases at HJH from 1^st May 2020 to 31^st April 2021. Data were collected by the National Institute for Communicable Diseases (NICD). Bivariate analysis was performed to describe and compare the socio-demographic characteristics, clinical characteristics, and hospital admission outcomes between the two waves. Multivariate logistic regression was used to determine risk factors for COVID-19-related mortality.

Results

overall, 1359 patients were admitted, 595 in wave one, and 764 in wave two. Patients were predominantly male (52.4%), of Black African race (75.1%) with a mean age of 54.6 (standard deviation 15.4) years. The median length of stay was 8 days (interquartile range 5-14 days). In total, 73.2% (995) of patients required oxygen, 5.2% (71) of patients received mechanical ventilation, and 7.1% (96) were admitted to the high care and Intensive Care Unit (ICU). The most common comorbid illnesses were hypertension (36.7%, n=499), diabetes mellitus (26.6%, n=362), Human Immunodeficiency Virus (HIV) (10.8%, n=147), and obesity (11.0%, n=149). The in-hospital CFR during the first wave was 30.4% (181/595) and 25.5% (195/764) (p<0.001) in the second wave, and overall, in-hospital CFR was 27.7% (376/1359). The adjusted odds of death were 79% higher among patients admitted during wave one compared to wave two (aOR=1.79; 95% CI: 1.35-2.38). A one-year increase in age increased the odds of death by 4% (aOR=1.04; 95% CI: 1.03-1.05). The need for oxygen (aOR=2.17, 95%CI: 1.56-3.01) and ventilation (aOR=7.23, 95% CI: 4.02-13.01) were significant risk factors for mortality.

Conclusion

prior to the availability of vaccines, COVID-19-related mortality was high and risk factors for mortality were consistent with national and international findings. This study reflects the impact of the pandemic on the South African public sector with limited resources and minimal ICU capacity.

Prospective cohort of COVID-19 patients requiring hospital admission in Douala, Cameroon

OBJECTIVES

To report characteristics and outcome of COVID-19 patients who required hospital admission in sub-Saharan Africa clinics with no access to invasive mechanical ventilation.

METHODS

Between April and June 2021, documented COVID-19 patients with SaO₂ <95% who were admitted in two clinics in Douala (Cameroon) were invited to participate. Data were prospectively collected using a standardized questionnaire.

RESULTS

We included 67 patients: 39 males (58%), median age 62 years [50-70]. Comorbidities included hypertension (n=38, 57%), obesity (n=26, 38%), and diabetes (n=16, 24%). No patient reported COVID-19 vaccination. On admission, 35 patients (52%) required O₂ >6L/min. CT scan demonstrated extended lesions (>50%) in 50/61 cases (82%). Most patients received dexamethasone (n=64, 96%), heparin (n=64, 96%), chloroquine/azithromycin (n=59, 88%), and broad-spectrum antibiotics (n=59, 88%). Sixteen patients died (24%), after a median of 11.5 days [7.5-15.5] post-admission.

CONCLUSIONS

Despite the lack of invasive mechanical ventilation, 76% of COVID-19 patients survived.